The scientific basis of drug-drug interactions: Mechanism and preclinical evaluation

Drug Information Journal

Volumn 32, Issue 3, 1998, Pages 657-664

  Albert, P L I ^a  

^a In Vitro Technologies Inc   (United States)

Author keywords

Drug drug interactions; Hepatocytes; Human; In vitro systems; Liver

Indexed keywords

DRUG CLEARANCE; DRUG INTERACTION; DRUG MECHANISM; ENZYME METABOLISM; HUMAN; IN VITRO STUDY; LIVER MICROSOME; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; REVIEW;

EID: 3543017295     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena Jr. LR. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
2. PDA. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA. 1992;268:705.
3. Pohjala-Sintonen S, Viitsalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. Brit Med J. 1993;306:186.
4. Yun CH, Okerholm A, Guengerich FP. Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P4503A(4) in N-dealkylation and C-hydroxylation. Drug Metab Disp. 1993;21:403-409.
5. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
6. D'Arcy PR Drug interactions with oral contraceptives. Drug Intell Clin Pharm. 1986;20:353-362.
7. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf. 1994;11:242-251.
8. Strolin Benedetti M, Dosiert P Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect. 1994;102:101-105.
9. Ged C, Roullion JM, Pichard L, Combalbert J, Bressot N, Bones P, Michel H, Beaune P, Maurel P. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol. 1989;38:373-387.
10. Li AP, Xu L, Rasmussen A, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther. 1995;274:673-677.
11. Li AP, Jurirna-Romet M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 1997;13:365-374.
12. Guengerich FP. Metabolism of 17a-ethynylestradiol in humans. Life Sci. 1990;47:1981-1988.
13. Reimers D, Nocke-Finck L, Breuer H. Rifampicin and the "pill" do not go well together. JAMA. 1974;227:608.
14. Barbarash RA. Verapamil-rifampin interaction. Drug Inlell Clin Pharm. 1985;19:559-560.
15. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996;24:796-801.
16. Herbert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992;52:453-457.
17. Lang R, Shasha B, Rubinstein E. Therapy of experimental murine burcellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother. 1993;37:2333-2336.
18. Colmenero JD, Fernandez-Gallardo LC, Agundez JA, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction in the treatment of brucellosis. Antimicrob Agents Chemother. 1994;38:2798-2802.
19. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum intraconazole (letter). Clin Infect Dis. 1994;18:266.
20. Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG. Time course of the changes in prednisolone pharmacokinetics after coadministration or discontinuation of rifampin. Eur J Clin Pharmacol. 1993;45:287-289.
21. Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993;37:1426-1431.
22. Gallicano K, Sahai J, Foster B, Bouchard J, Cameron DW. Rifampin decreases zidovudine plasma concentrations in HIV infected patients. Abstract No. 425; 4th Conference on Retrovirus and Opportunistic Infections. Washington, DC: January 1997.
23. Rodrigues AD. Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem Pharmacol. 1994;48:2147-2156.
24. Li AP, Roque MA, Beck DJ, Kaminski DL. Isolation and culturing of hepatocytes from human liver. J Tiss Culture Methods 1992;14:139-146.
25. Li AP. Primary hepatocyte culture as an in vitro toxicologicai system. In: Shayne Gad, ed. In Vitro Toxicology. New York, NY: Raven Press; 1994:195-220.
26. Li AP. Primary hepatocyte cultures as an experimental model for the evaluation of pharmacokinetic drug-drug interactions. In: Albert P. Li, ed. Drug-drug interactions: scientific and regulatory perspectives. San Diego, CA; Academic Press; 1997:103-130.
27. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug-drug interactions: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 incution. Chemico-biological Interactions. 1998;107:5-16.
28. Krumdieck CL, Dos Santos JE, Ho KJ. A new instrument for the rapid preparation of tissue slices. Anal Biochem. 1980;104:118-123.
29. Brendel K, Gandolfi AJ, Krumdieck CL, Smith PF. Tissue slicing and culturing revisited. Trends Pharm Sci. 1987;8:11-15.
30. Vickers AEM, Fischer V, Connors S, Fisher RL, Baldeck JP, Maurer G, Brendel K. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos. 1992;20:802-809.
31. Crespi CL, Gonzalez FJ, Steimel DT, Turner TR, Gelboin HV, Penman BW, Langenbach R. A metabolically competent cell line expressing five cDNAs encoding procarcinogen-activating enzymes: applications to mutagenicity testing. Chem Res Toxicol. 1991;4:566-572.
32. Crespi CL, Langenbach R, Penman BW. Human cell lines, derived from AHH-1 TK-+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicol 1993;82:89-104.
33. Gillam EMJ, Baba T, Kim BR, Ohmori S, Guengerich FP. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys. 1993;305:123-131.
34. Butlers JTM, Korzekwa KR, Kunze KL, Omata Y, Harwick JP, Gonzalez FJ. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Disp. 1994;22:688-692.
35. Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression systems. Ann Rev Pharmacol Toxicol. 1995;35:369-390.
36. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P4503A4. Toxicol. 1995a;104:1-8.
37. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev. 1993;25:453-484.
38. Jurima-Romet M, Huang HS, Beck DJ, Li AP. Metabolism of terfenadine and its inhibition in primary human and rat hepatocytes and HepG2 cells. Toxicol in Vitro. 10:655-663.